InflaRx N.V Asset Resilience Ratio
InflaRx N.V asset resilience ratio. InflaRx N.V (IF0) has an Asset Resilience Ratio of 55.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IF0 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of InflaRx N.V (2018–2025)
Asset resilience ratio of InflaRx N.V from 2018 to 2025. This chart shows how InflaRx N.V's Asset Resilience Ratio has changed over time. Read IF0 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down InflaRx N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is InflaRx N.V's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €30.44 Million | 55.12% |
| Total Liquid Assets | €30.44 Million | 55.12% |
Asset Resilience Insights
- Very High Liquidity: InflaRx N.V maintains exceptional liquid asset reserves at 55.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
InflaRx N.V Industry Peers by Asset Resilience Ratio
Compare InflaRx N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
InflaRx N.V Asset Resilience Ratio by Year (2018–2025)
InflaRx N.V asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for InflaRx N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.12% | €30.44 Million ≈ $35.58 Million |
€55.22 Million ≈ $64.55 Million |
+9.79pp |
| 2024-12-31 | 45.33% | €34.46 Million ≈ $40.29 Million |
€76.02 Million ≈ $88.87 Million |
-19.14pp |
| 2023-12-31 | 64.48% | €77.50 Million ≈ $90.61 Million |
€120.21 Million ≈ $140.54 Million |
+0.47pp |
| 2022-12-31 | 64.01% | €65.54 Million ≈ $76.63 Million |
€102.40 Million ≈ $119.72 Million |
+18.33pp |
| 2021-12-31 | 45.68% | €57.16 Million ≈ $66.83 Million |
€125.14 Million ≈ $146.30 Million |
-16.85pp |
| 2020-12-31 | 62.53% | €55.16 Million ≈ $64.49 Million |
€88.22 Million ≈ $103.13 Million |
-5.21pp |
| 2019-12-31 | 67.74% | €82.35 Million ≈ $96.28 Million |
€121.58 Million ≈ $142.14 Million |
+4.19pp |
| 2018-12-31 | 63.55% | €101.18 Million ≈ $118.29 Million |
€159.21 Million ≈ $186.14 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more